AZ begins liver cancer immunotherapy tie-up with AVEOAstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in Share XAZ begins liver cancer immunotherapy tie-up with AVEOhttps://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/
AstraZeneca looks to CRISPR to boost success ratesBetween 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share XAstraZeneca looks to CRISPR to boost success rateshttps://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/
AZ and CRUK team up to go all-in on CRISPRAstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling Share XAZ and CRUK team up to go all-in on CRISPRhttps://pharmaphorum.com/news/az-cruk-crispr/
AZ’s cancer drug fails again, Roche’s rival gets new useAstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved Share XAZ’s cancer drug fails again, Roche’s rival gets new usehttps://pharmaphorum.com/news/azs-cancer-imfinzi-fail/
AstraZeneca searching for Pascal Soriot successor – reportAstraZeneca is looking for a successor to CEO Pascal Soriot just in case he decides to move on, Share XAstraZeneca searching for Pascal Soriot successor – reporthttps://pharmaphorum.com/news/astrazeneca-searching-for-pascal-soriot-successor-report/
AstraZeneca’s immunotherapy fails in key lung cancer trialAstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line Share XAstraZeneca’s immunotherapy fails in key lung cancer trialhttps://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-key-lung-cancer-trial/
The future of pharma in a digital worldHow is digital health impacting pharma? An exclusive live broadcast from Frontiers Health 2018 addressed this subject on Share XThe future of pharma in a digital worldhttps://pharmaphorum.com/digital/healthlive-the-future-of-pharma-in-a-digital-world/
AstraZeneca may have hit rock bottom, but can it rise to new heights?Back in 2014, Pascal Soriot CEO of AstraZeneca managed to stave off a takeover bid from Pfizer with Share XAstraZeneca may have hit rock bottom, but can it rise to new heights?https://pharmaphorum.com/views-analysis-sales-marketing/astrazeneca-rise-new-heights/
AZ sells rights to RSV virus drug to Sobi for $1.5bnAstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for Share XAZ sells rights to RSV virus drug to Sobi for $1.5bnhttps://pharmaphorum.com/news/az-sells-rights-to-rsv-virus-drug-to-sobi-for-1-5bn/
